Literature DB >> 23208300

Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women.

Linlin Cui1, Han Zhao, Bo Zhang, Zhongyu Qu, Jiayin Liu, Xiaoyan Liang, Xiaoming Zhao, Junli Zhao, Yingpu Sun, Peng Wang, Tao Li, Yuhua Shi, Zi-Jiang Chen.   

Abstract

STUDY QUESTION: Are there any correlations between the phenotypes of polycystic ovary syndrome (PCOS) and the genotypes of the PCOS susceptibility single nucleotide polymorphisms (SNPs) in THADA, DENND1A and LHCGR? SUMMARY ANSWER: The PCOS susceptibility genes, THADA and DENND1A, carry risk alleles that are associated with endocrine and metabolic disturbances in patients with PCOS. WHAT IS KNOWN ALREADY: PCOS is a heterogeneous endocrinopathy characterized by oligo-anovulation, hyperandrogenism and polycystic ovaries. In a previous genome-wide association study, the SNP variants rs13429458, rs12478601, rs2479106, rs10818854 and rs13405728 in the THADA, DENND1A and LHCGR genes were identified as being independently associated with PCOS. The aim of this study was to identify any additional correlations between the phenotypes of PCOS and genotypes of the five SNPs described in the previous study. STUDY DESIGN, SIZE, DURATION: In the present cross-sectional study, a total of 1731 PCOS patients and 4964 controls were enrolled. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Patients were diagnosed according to Rotterdam criteria. Clinical information was collected from the patients and controls. Endocrine and metabolic parameters were evaluated for phenotype-genotype correlation analyses. MAIN RESULTS AND THE ROLE OF CHANCE: Using a recessive model, the AA group for rs13429458 in THADA was associated with increased luteinizing hormone (LH) (P < 0.01) and testosterone (T) (P = 0.02) levels in subjects with PCOS; the LH/follicle-stimulating hormone ratio was also higher in the AA group (P < 0.01). Also using a recessive model, the CC genotype of rs12478601, also in THADA, was associated with increased levels of low-density lipoprotein (P = 0.02). Using a dominant model, the GG + AG group for rs2479106 in DENND1A was associated with elevated serum insulin levels 2 h after a glucose load in the patients with PCOS (P = 0.02). All of the comparisons were adjusted for age and BMI. LIMITATIONS, REASONS FOR CAUTION: The relatively younger age of the participants may represent a considerable bias when evaluating metabolic alterations as a function of different genotypes, as significant metabolic disturbances may emerge later in life. Furthermore, the sample sizes of several sub-genotype groups were relatively small; to some extent this limited the statistical power of the analysis. WIDER IMPLICATIONS OF THE
FINDINGS: The PCOS susceptibility genes, THADA and DENND1A, carry risk alleles that are associated with endocrine and metabolic disturbances in PCOS patients of Han Chinese descent. The findings have shown genuine heterogeneity, stratified on the basis of both clinical findings and genotypes. Replication of these results is expected in other ethnic groups.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23208300     DOI: 10.1093/humrep/des424

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  37 in total

1.  Leutinizing hormone/choriogonadotropin receptor and follicle stimulating hormone receptor gene variants in polycystic ovary syndrome.

Authors:  Wassim Y Almawi; Bayan Hubail; Dana Z Arekat; Suhaila M Al-Farsi; Shadha K Al-Kindi; Mona R Arekat; Naeema Mahmood; Samira Madan
Journal:  J Assist Reprod Genet       Date:  2015-02-04       Impact factor: 3.412

2.  The role of DENND1A and CYP19A1 gene variants in individual susceptibility to obesity in Turkish population-a preliminary study.

Authors:  Ela Kadioglu; Beril Altun; Çağrı İpek; Esra Döğer; Aysun Bideci; Hadi Attaran; İsmet Çok
Journal:  Mol Biol Rep       Date:  2018-09-19       Impact factor: 2.316

3.  miRNA Profiling Reveals miRNA-130b-3p Mediates DENND1A Variant 2 Expression and Androgen Biosynthesis.

Authors:  Jan M McAllister; Angela X Han; Bhavi P Modi; Maria E Teves; Grace R Mavodza; Zachary L Anderson; Tsaiwei Shen; Lane K Christenson; Kellie J Archer; Jerome F Strauss
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

4.  Polymorphisms of pentanucleotide repeats (tttta)n in the promoter of CYP11A1 and their relationships to polycystic ovary syndrome (PCOS) risk: a meta-analysis.

Authors:  Min Yu; Ruizhi Feng; Xiaoxi Sun; Haojue Wang; Huan Wang; Qing Sang; Li Jin; Lin He; Lei Wang
Journal:  Mol Biol Rep       Date:  2014-03-09       Impact factor: 2.316

Review 5.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 6.  Genetics of polycystic ovary syndrome.

Authors:  Corrine K Welt; Jessica M Duran
Journal:  Semin Reprod Med       Date:  2014-04-08       Impact factor: 1.303

7.  American, European, and Chinese practice guidelines or consensuses of polycystic ovary syndrome: a comparative analysis.

Authors:  Fang-Fang Wang; Jie-Xue Pan; Yan Wu; Yu-Hang Zhu; Paul J Hardiman; Fan Qu
Journal:  J Zhejiang Univ Sci B       Date:  2018-05       Impact factor: 3.066

8.  Association study of polymorphism of FXIIIVal34Leu gene and polycystic ovary syndrome.

Authors:  Xuefeng Wang; Yue Yang; Yanbing Huang; Qiongyao Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

9.  Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis.

Authors:  Ying Liu; Mei-Guo Sun; Rong Jiang; Rui Ding; Zhen Che; Yan-Yan Chen; Ci-Jiang Yao; Xiao-Xia Zhu; Ji-Yu Cao
Journal:  J Assist Reprod Genet       Date:  2014-01-17       Impact factor: 3.412

Review 10.  Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: insight from animal models.

Authors:  Alison V Roland; Suzanne M Moenter
Journal:  Front Neuroendocrinol       Date:  2014-04-18       Impact factor: 8.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.